Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™

Kennewick, WA, June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy (PRnT) with its innovative RadioGel technology, today announced the submission of its Early Feasibility IDE application to the FDA. This milestone represents a significant advancement in the Company's regulatory pathway and builds directly on the substantial progress detailed in its February 10, 2026 update.